Making the first decision: EGFR mutation-positive NSCLC in the advanced setting
|
|
- Maurice Mosley
- 6 years ago
- Views:
Transcription
1 ELCC May 217, Switzerland Making the first decision: EGFR mutation-positive NSCLC in the advanced setting Noemí Reguart, MD, PhD Hospital Clínic de Barcelona, Spain
2 Disclosures Consultant or Advisory Role Merck Sharp & Dohme, Bristol-Myers Squibb, Roche, Boehringer Ingelheim, Guardant Health, Pfizer Grant/Trial Funding Roche 2
3 Disclaimer Afatinib is approved in a number of markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF and in the US under the brand name GILOTRIF for use in patients with distinct types of EGFR mutation positive NSCLC. In Switzerland, GIOTRIF is indicated as monotherapy for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naïve patients with stage IIIB/IV non-small cell lung cancer (NSCLC) with common activating EGFR mutation(s) (exon 19 deletions or exon 21 L858R substitution). The recommended dose is 4 mg once daily with no possibility for dose escalation. Registration conditions differ internationally, please refer to locally approved prescribing information. Afatinib is under regulatory review by health authorities in other countries worldwide. Afatinib is not approved in uncommon mutations and SqCC of the Lung and other indications in Switzerland. 3
4 The journey of a patient with EGFR mutation-positive NSCLC RESISTANCE First-line therapy Second-line therapy NSCLC (Stage IV) EGFR activating mutation First generation (erlotinib, gefitinib) or second generation (afatinib) TKI T79M ~5%, most common 1,4,5 MET amplification ~5 11% 1,4 Unknown 3% 4 Osimertinib (FDA, EMA approved) C-MET inhibitor (clinical trials) Chemotherapy Molecular driver mutations in NSCLC 2 Resistance mechanisms to EGFR TKIs 4 3% EGFR 3 : ~ 15% (Western population) ~ 3% (Asian population) 5% 14% 5% 49% KRAS BRAF PIK3CA MEK AKT1 ROS1 translocation EGFR ALK translocation HER2 NRAS RET translocation Other With EGFR amp MET amp PIK3CA T79M SCLC transformation Unknown mechanism ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; EMA, European Medicines Agency; FDA, Food and Drug Administration; HER2, human epidermal 4 growth factor receptor 2; NSCLC, non-small lung cancer; SCLC, small cell lung cancer; TKI, tyrosine kinase inhibitor. 1. Arcila ME, et al. Clin. Cancer Res. 211;17(5):1169 8; 2. Baumgart M. AJHO. 215: 3. Van Assche K, et al. Front Oncol ;4:35. doi: /fonc ; 4, Sequist LV, et al. Sci Transl Med. 211;3(75):75ra26; 5. Wang S, et al. J Hematol Oncol. 216;9:34.
5 CASE 1
6 Case 1 History Female, 6 years old, healthy, no related comorbidities, non-smoker, ECOG PS 1 First diagnosis (December 214) Lung adenocarcinoma (IHC: TTF-1 and CK7 positive) Staging: ct1bnm1 (IVb, solitary brain metastasis) First treatment (January 215) Resection of the brain metastasis and lobectomy (pt1bn1) WBRT 3 Gy 1 fx plus adjuvant chemotherapy (4 cycles platinum vinorelbine) First imaging assessment (June 215) PET-CT: multiple bone metastases MRI: no evidence of recurrence in the brain Molecular characterisation Exon 19 (EGFR T751_I759delinsS) by COBAS-Therascreen 6 Case report: N. Reguart. CK7, cytokeratin 7; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; IHC, immunohistochemistry; PET-CT, positron emission tomography computed tomography; TTF-1, thyroid transcription factor-1; WBRT, whole brain radiation therapy; MRI, magnetic resonance imaging.
7 Case 1: images at diagnosis MRI PET-CT ct1bnm1 (IVb, solitary brain metastasis) Radical treatment indicated (January 215). Case report: N. Reguart PET-CT, positron emission tomography computed tomography; MRI, magnetic resonance imaging. 7
8 Case 1: images at systemic relapse MRI PET-CT Early systemic metastatic bone relapse (June 215) 8 Case report: N. Reguart. PET-CT, positron emission tomography computed tomography; MRI, magnetic resonance imaging.
9 Currently approved EGFR-TKIs: guiding selection of treatment in the clinic First generation Erlotinib Gefitinib Second generation Afatinib Third generation Osimertinib Outcomes of TKIs (response, duration, survival) Molecular: mutation type (Del19/L858R/T79M) Phenotypic features (age, gender, weight, ethnicity) Risk of toxicity Brain disease (presence/absence) 9 EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.
10 EGFR-targeted TKIs: clinical benefits in EGFR mutation-positive NSCLC Randomised controlled trials TKI Studies EGFR mutation (n) PFS HR (95% CI) OS HR (95% CI) Gefitinib IPASS 1 3 EGFR M+ (n=261)* Del19 (n=14) L858R (n=111).48 (.36.64).38 (.26.56).55 (.35.87) 1. ( ).79 ( ) 1.44 (.9 2.3) Gefitinib WJTOG 4,5 Common (n=172).49 (.34.71) 1.25 ( ) Gefitinib NEJ2 3,6 EGFR M+ (n=224) Del19 (n=116) L858R (n=97).32 (.24.44).35 (.23.52).32 (.2.5).89 ( ).83 ( ).82 ( ) Erlotinib OPTIMAL 7,8 Common (n=154).16 (.1.26) 1.19 ( ) Erlotinib EURTAC 9,1 Common (n=173).34 (.23.49).93 ( ) Erlotinib ENSURE 11 Common (n=217).34 (.22.51).91 ( ) Afatinib LUX-Lung EGFR M+ (n=345).58 (.43.78).88 ( ) Afatinib LUX-Lung EGFR M+ (n=364).28 (.2.39).93 ( ) Findings from several Phase III trials demonstrate benefit in RR, PFS and QoL, but no differences observed in OS *Out of a total of 1,217 patients. CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; M+, mutation positive; OS, overall survival; NSCLC, non-small cell lung cancer; PFS, progression-free survival; QoL, quality of life; RR, response rate; TKI, tyrosine kinase inhibitor Mok TS, et al. N Engl J Med 29;361:947 57; 2. Fukuoka M, et al. J Clin Oncol 211;29: ; 3. Yang JC, et al. Eur J Cancer 211; (suppl 1):S633 (poster 9132); 4. Mitsudomi T, et al. Lancet Oncol 21;11:121 8; 5. Yoshioka H, et al. J Clin Oncol 214;32(Suppl.): Abstract 8117; 6. Inoue A, et al. Ann Oncol 213;24:54 9; 7. Zhou C, et al. Lancet Oncol 211;12:735 42; 8. Zhou C, et al. Ann Oncol 215;26: ; 9. Rosell R, et al. Lancet Oncol 212;13:239 46; 1. Khozin S, et al. Oncologist 214;19:774 9; 11. Wu YL, et al. Ann Oncol 215;26:1883 9; 12. Sequist LV, et al. J Clin Oncol 213;31: ;13. Yang JC, et al. Lancet Oncol 215;16:141 51; 14. GIOTRIF EU SmPC, as approved July 215; 15. Wu YL, et al. Lancet Oncol 214;15:
11 Estimated OS probability Estimated OS probability LUX-Lung 3 and 6: preplanned OS analysis by mutation subgroups LUX-Lung 3: Del 19 LUX-Lung 6: Del Afatinib (n=112) Cis/pem (n=57) 1. Afatinib (n=124) Cis/gem (n=62).8 Median, months HR (95% CI) p value (.36.79) p=.15.8 Median, months HR (95% CI) p value (.44.94) p= Time (months) No. at risk: Afatinib Cis/pem Time (months) No. at risk: Afatinib Cis/gem L858R LUX-Lung 3 LUX-Lung 6 Afatinib (n=91) Cis/pem (n=47) Afatinib (n=92) Cis/gem (n=46) Median, months HR (95% CI), p value 1.3 ( ), p= ( ), p= CI, confidence interval; cis, cisplatin; gem, gemcitabine; HR, hazard ratio; pem, pemetrexed; OS, overall survival. Yang JC, et al. Lancet Oncol 215;16:
12 LUX-Lung 7: Randomised trial evaluating two EGFR-directed therapies in EGFRm NSCLC Patients (N=319) Stage IIIB/IV adenocarcinoma of the lung EGFR mutation (Del19 and/or L858R) in the tumour tissue* No prior treatment for advanced/metastatic disease ECOG PS /1 n=16 1:1 n=159 Afatinib 4 mg QD Stratified by: Mutation type (Del19/L858R) Brain metastases (present/absent) Gefitinib 25 mg QD Co-primary endpoints: PFS (independent review) TTF OS Secondary endpoints: ORR Time to response Duration of response Tumour shrinkage HRQoL Treatment beyond progression allowed if deemed beneficial by investigator RECIST assessment performed at Weeks 4 and 8, and every 8 weeks thereafter until Week 64, and every 12 weeks thereafter Primary PFS analysis conducted after ~25 events; primary OS analysis conducted after ~213 events and 32-month follow-up All statistical testing at two-sided 5% alpha level with no adjustment for multiplicity *Central or local test; Dose modification to 5, 3 or 2 mg was permitted in line with prescribing information. 12 ECOG PS, Eastern Cooperative Oncology Group performance status; HRQoL, health-related quality of life; NSCLC, non-small cell lung cancer; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; QD, once daily; RECIST, Response Evaluation Criteria In Solid Tumors; TTF, time to treatment failure. Park K, et al. Lancet Oncol 216;17:
13 In your clinical practice, which outcome is the most relevant for informing treatment decisions?? 1. OS 2. TTF 3. PFS by independent review 13 OS, overall survival; PFS, progression-free survival; TTF, time to treatment failure.
14 PFS (%) LUX-Lung 7: PFS in the overall population by independent central review 1 Afatinib (n=16) Gefitinib (n=159) 8 6 Median PFS, months HR (95% CI) p value.73 (.57.95) No. at risk: Time of PFS (months) Afatinib Gefitinib CI, confidence interval; HR, hazard ratio; PFS, progression free survival. Park K, et al. Lancet Oncol 216;17:
15 Estimated OS probability LUX-Lung 7: OS in the overall population 1. Afatinib Gefitinib.8 Median, months HR (95% CI) p value.86 ( ).258* Median follow-up: 42.6 months (as of 8 April 216) Median treatment duration (afatinib vs gefitinib): 13.7 vs 11.5 months No. at risk: Time (months) Afatinib Gefitinib *Unadjusted. 15 CI, confidence interval; HR, hazard ratio; OS, overall survival. Paz-Ares L, et al. Ann Oncol 217; 28:
16 Estimated OS probability Estimated OS probability LUX-Lung 7: OS and response by EGFR mutation subtype Del 19 1 L858R 1 1. Afatinib Gefitinib Median,months Afatinib Gefitinib Median,months HR (95% CI) p-value.83 ( ) HR (95% CI) p-value.91 ( ) No. at risk: Afatinib Gefitinib Time (months) No. at risk: Afatinib Gefitinib Time (months) Exon 19 Del Leu858Arg Mutation subtype 2 Afatinib Gefitinib Afatinib Gefirinib Response rate Rate (%) (%) 73% 66% 66% 42% 16 CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; OS, overall survival. 1. Paz-Ares L, et al. Ann Oncol 217; 28:27 277; 2. Park K, et al. Lancet Oncol 216;17:
17 Case 1: early PR after 6 weeks on afatinib Pretreatment (June 215) 6 weeks on afatinib 4 mg QD (August 215) PET-CT early response with afatinib 4 mg QD 19 PET-CT, positron emission tomography-computed tomography; PR, partial response; QD, once daily. Case report: N. Reguart.
18 LUX-Lung 7: drug-related AEs (>1%) 1 Afatinib (n=16) Gefitinib (n=159) All Grade 3* All Grade 3* Any AE, n (%) 156 (97.5) 5 (31.3) 153 (96.2) 31 (19.5) Diarrhoea 144 (9.) 21 (13.1) 97 (61.) 2 (1.3) Rash/Acne 142 (88.8) 15 (9.4) 129 (81.1) 5 (3.1) Stomatitis 13 (64.4) 7 (4.4) 38 (23.9) Paronychia 9 (56.3) 3 (1.9) 28 (17.6) 1 (.6) Dry skin 52 (32.5) 59 (37.1) Pruritus 37 (23.1) 36 (22.6) Fatigue 33 (2.6) 9 (5.6) 23 (14.5) ALT increased 15 (9.4) 38 (23.9) 13 (8.2) AST increased 1 (6.3) 33 (2.8) 4 (2.5) Higher number of AEs leading to dose reduction with afatinib (42% vs 2%) 2 Four cases of drug-related ILD were observed with gefitinib (three Grade 3); none were observed with afatinib 1 *All Grade 3 unless stated; Including one (.6%) Grade 4 AE; Grouped term. 2 AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ILD, interstitial lung disease. 1. Paz-Ares L, et al. Ann Oncol 217; 28: (supplementary table S2); 2. Park K, et al. Lancet Oncol 216;17:
19 Patients (%) LUX-Lung 7: drug-related AEs leading to discontinuation in more than one patient (3.1%) 5 (3.1%) 4 (2.5%) Afatinib Gefitinib 2 3 (1.9%) 2 (1.3%) 2 (1.3%) 1 % % % % % % Diarrhoea Fatigue* Toxic skin eruption ALT increase AST increase ILD Low rate of treatment discontinuation (6%) in both arms *Grouped term. 21 AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ILD, interstitial lung disease. Park K, et al. Lancet Oncol 216;17: (supplementary material); Park K, et al. Ann Oncol 215;26(Suppl. 9): Abstract LBA2 (oral presentation).
20 Patients (%) Influence of dose adjustment on afatinib safety: post-hoc analysis LUX-Lung 3 Median treatment exposure for dose-reduced patients 1 Key treatment-related AEs in patients requiring tolerability-guided dose adjustment 1,2 Median treatment exposure (days) Grade 3 Grade 1/2 4 mg (n=122) mg (n=12) mg (n=4) Pre Post Pre Post Pre Post Pre Post Pre Post Any Diarrhoea Rash/acne* Stomatitis Nail effects* Pre: AEs before dose reduction from 4 mg Post: AEs after first dose reduction from 4 mg Despite longer treatment exposure at lower doses, tolerability-guided dose reduction led to decreases in the incidence and severity of treatment-related AEs 22 * Grouped term. AE, adverse event. 1. Yang JC, et al. J Clin Oncol 215;33(Suppl.): Abstract 873 (poster); 2. Yang JC, et al. Ann Oncol 216;27:213 1.
21 Identifying groups of risk for afatinib AEs 3 Factors associated with severe GI toxicity and DLT induced by afatinib in patients with advanced NSCLC 1 HR 95% CI p value Severe GI toxicity Female Age, years ECOG PS Weight, kg Malnourished DLT Body surface, m Malnourished Post-hoc analysis LUX-Lung 3: dose reductions more common in females, older patients, East Asian ethnicity, low body weight (<5 kg) and low body surface m 2 (BSA) 2 23 AE, adverse event; BSA, body surface area; CI, confidence interval; DLT, dose-limiting toxicity; ECOG PS, Eastern Cooperative Oncology Group performance status; GI, gastrointestinal; HR, hazard ratio; NSCLC, non-small cell lung cancer. 1. Arrieta O, et al. Oncologist 215;2:967 74; 2. Yang J, et al. J Clin Oncol 215;33(Suppl.): abstract 873 (poster).
22 Estimated PFS probability Influence of dose adjustment on afatinib efficacy: post-hoc analysis LUX-Lung 3 Median PFS similar in patients who had afatinib dose reductions in the first 6 months and those who remained on afatinib 4 mg QD <4 mg in first 6 months (n=15) 4 mg in first 6 months (n=124) Median, months HR (95% CI) p value 1.25 ( ).175 <4 mg in first 6 months 4 mg in first 6 months.2 No. at risk in first 6 months <4 mg 4 mg Time (months) CI, confidence interval; HR, hazard ratio; PFS, progression-free survival; QD, once daily. Yang JC, et al. Ann Oncol 216;27:213 1.
23 Long-term response independent of dose adjustment: Post-hoc analysis LUX-Lung 7 Long-term treatment (>3 years) was independent of tolerability-guided dose adjustment, or the presence of brain metastases at time of enrolment *Patients were ordered and numbered by treatment duration, with Patient 1 being on treatment longest; At the time of enrolment. 25 LTR, long-term responders; OS, overall survival. 1. Schuler M, et al. ECCO 217 (oral presentation).
24 Approximately what proportion of your patients require tolerability-guided dose adjustment of afatinib?? 1. The majority of patients 2. About half of patients 3. Very few patients 26
25 Proactive management and close monitoring to prevent class-effect AEs Days/cycle Follow up Goal D+2/D+3 Phone call or visit* Early detection of GI toxicity D+7 First follow-up visit Early detection of possible class-effect AEs (diarrhoea and rash) D+3 and every cycle Monthly follow-up visit Monthly follow-up of patient evolution Afatinib started 4 mg QD Recommended follow-up schedule 1 Case report Afatinib reduced 3 mg QD Cycle 1 Cycle 2 Cycle 3 Day 3 Day 7 Day 38 Day 41 Bone pain opioids Oncology nurse phone call; optimal care Physician visit: afatinib 4 mg QD continued Oncology nurse phone call; optimal care Physician visit: afatinib stopped No bone pain opioids discontinued Diarrhoea G2 Diarrhoea G1 Diarrhoea G2 Diarrhoea G2 Diarrhoea G1 *By an oncologist or an oncology nurse on the basis of the hospital/centre organisation. 27 AE, adverse events; D, day; G, grade; GI, gastrointestinal; QD, once daily. 1. Arriola E, et al. Future Oncol 215;11: Case report: N. Reguart.
26 Case 1: PET-CT scans show CR after 22 months on afatinib 3 mg QD Pretreatment (June 215) 6 weeks on afatinib 4 mg QD (August 215) 22 months on afatinib 3 mg QD (April 217) Long-term and broader response with afatinib despite dose reduction 28 CR, complete response; PET-CT, positron emission tomography computed tomography; QD, once daily. Case report: N. Reguart.
27 CASE 2
28 Case 2 History Female patient, 58 years old, no past medical history, non-smoker Diagnosis April 215 Stage IVb NSCLC (ct2nm1b), gastro-hepatic ligament lymph nodes Molecular profiling: dpcr-egfr WT, ALK/ROS non-translocated Treatment evolution First line: Platinum doublet; PR as best response (October 215) Symptomatic progression at brain (January 216) Second line: Nivolumab 3 mg/kg q2w and WBRT (TD 3 Gy/1 fx) Symptomatic progression at brain and primary tumour (May 216) 3 ALK, anaplastic lymphoma kinase; dpcr, digital polymerase chain reaction; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; PR, partial response; q2w, once every 2 weeks; ROS, c-ros oncogene; WBRT, whole brain radiation therapy; WT, wild type. Case report: N. Reguart.
29 Case 2: CT scans on nivolumab progression in second line Progressive disease in brain and lung after 3 cycles (May 216) Significant oedema observed 31 CT, computerised tomography. Case report: N. Reguart.
30 Case 2: Rebiopsies to guide targeted treatment April 215 Initial presentation January 216 Progression on chemotherapy May 216 Progression on nivolumab June 216 Blood sample Liquid biopsy 1 st biopsy 2 nd biopsy 3 rd biopsy Liquid biopsy 1 st Biopsy-lung EGFR WT (dpcr) no fusion ALK ROS (FISH) No tissue available for retesting 2 nd Biopsy-lung No tissue available 3 rd Biopsy-lung No tissue available Pneumothorax 32 ALK, anaplastic lymphoma kinase; dpcr, digital polymerase chain reaction; EGFR, epidermal growth factor receptor; FISH, fluorescent in situ hybridisation; WT, wild type; ROS, c-ros oncogene. Case report: N. Reguart.
31 Case 2: liquid biopsy report Summary of alterations Tumour response map Alteration % cfdna cfdna amplification Somatic alteration burden 6.8% Exon 19 Deletion 6.8 EGFR AMP + PTEN E73* 2.5 BRCA1 Q78*.1 Guardant36 (v 2.1) Exon 19 deletion identified in liquid biopsy 34 AMP, amplification; BRCA1, breast cancer 1; EGFR, epidermal growth factor receptor; PTEN, phosphatase and tensin homolog. Case report: N. Reguart.
32 Does the presence of brain metastasis factor in your selection for a TKI?? 1. No 2. Yes 3. Only if asymptomatic 35 TKI, tyrosine kinase inhibitor.
33 Estimated PFS probability PFS in patients with brain metastases: combined analyses from LUX-Lung 3 and Afatinib (n=48) Chemo (n=33) Median PFS, months HR (95% CI) p value.5 (.27.95) No. at risk in first 6 months Afatinib Chemo Time (months) 17 1 Time to CNS progression in LUX-Lung 3 and 6 was superior than chemo in patients with brain metastasis (15.2 vs 5 7 months) CI, confidence interval; CNS, central nervous system; HR, hazard ratio; PFS, progression-free survival. Schuler M, et al. J Thorac Oncol 216;11:38 9.
34 Case 2: CT scans after 2 cycles of afatinib Pretreatment (June 216) 6 weeks on afatinib (August 216) 37 CT, computerised tomography. Case report: N. Reguart.
35 Summary Efficacy First-line afatinib showed a significant improvement in OS of over 1 year versus chemotherapy in EGFR Del 19 patients in two randomised trials 1 Results from LUX-Lung 7 confirm the significant benefit in PFS of afatinib over gefitinib in treatment of EGFR m+ NSCLC 2 Tolerability AEs with afatinib and gefitinib were manageable leading to equally low rates of treatment discontinuation (6.3% in both treatment arms) 1 Proactive management, close monitoring and dose adjustment can effectively manage AEs Identify groups of risk and adjust dose if necessary Brain metastasis CNS metastases negatively impact the quality of life and OS of many patients with NSCLC and continue to present a therapeutic challenge The magnitude of benefit in PFS with afatinib over chemotherapy was maintained in patients with asymptomatic brain metastases 3 38 AE, adverse event; Del, deletion; CNS, central nervous system; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; OS, overall survival; M+, mutation positive; PFS, progression-free survival. 1. Yang JC, et al. Lancet Oncol 215;16:141 51; 2. Park K, et al. Ann Oncol 215;26(Suppl. 9): Abstract LBA2 (presentation); 3. Schuler M, et al. J Thorac Oncol 216;11:38 9.
36 Faculty Discussion Chair Rolf Stahel University Hospital of Zürich, Switzerland David R. Gandara University of California Davis Cancer Center, USA Noemí Reguart Hospital Clínic de Barcelona, Spain Maximilian Hochmair Otto Wagner Spital, Vienna, Austria 4
Treatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationUnderstanding Options: When Should TKIs be Considered?
Advanced Stage Squamous NSCLC: Evolution and Increasing Complexity of the Therapeutic Landscape Understanding Options: When Should TKIs be Considered? David R. Gandara, MD University of California Davis
More informationSequencing in EGFR-Mutated NSCLC: Does Order Matter?
Sequencing in EGFR-Mutated NSCLC: Does Order Matter? Maximilian J. Hochmair, MD Otto Wagner Hospital Vienna, Austria Disclosures Honoraria: AstraZeneca, AbbVie, Pfizer, Boehringer Ingelheim, Roche, MSD,
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationImproving outcomes for NSCLC patients with brain metastases
Improving outcomes for NSCLC patients with brain metastases Martin Schuler West German Cancer Center, Essen, Germany In Switzerland, afatinib is approved as monotherapy for patients with non-small cell
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationEmerging Algorithm for Optimal Sequencing of EGFR TKIs in EGFR Mutation Positive NSCLC
Emerging Algorithm for Optimal Sequencing of EGFR TKIs in EGFR Mutation Positive NSCLC Keunchil Park, MD, PhD Samsung Medical Center, Sungkyunkwan University School of Medicine Faculty Disclosure Consulting
More informationTargeted Therapies for Advanced NSCLC
Targeted Therapies for Advanced NSCLC Current Clinical Developments Friday, June 3, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016 ASCO Annual Meeting
More informationEGFR TKI sequencing: does order matter?
EGFR TKI sequencing: does order matter? Nicolas Girard Thorax Institut Curie-Montsouris, Paris, France In Switzerland, afatinib is approved as monotherapy for patients with non-small cell lung cancer (Stage
More informationInhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS
Inhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS Driver Mutations to Classify Lung Cancer Unknown 36% KRAS 25% EGFR 15% ALK 4% HER2 2% Double Mut 2% BRAF 2% PIK3CA
More informationManagement Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors
Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors Conor E. Steuer, MD Assistant Professor The Winship Cancer Institute of Emory University July 27, 2017 1 Lung Cancer One
More informationState of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD
State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD Professor and Chair Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Nothing to disclose DISCLOSURE Objectives Lung
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationOsimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study
Osimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study Abstract 9002 Yang JC, Kim DW, Kim SW, Cho BC, Lee JS, Ye X, Yin X, Yang
More informationAfatinib in patients with EGFR mutation-positive NSCLC harboring uncommon mutations: overview of clinical data
Afatinib in patients with EGFR mutation-positive NSCLC harboring uncommon mutations: overview of clinical data Oscar Arrieta, 1 Pedro De Marchi, 2 Nobuyuki Yamamoto, 3 Chong-Jen Yu, 4 Sai-Hong I Ou, 5
More informationAFATINIB* 1. WHAT IS AFATINIB? 2. HOW DOES AFATINIB WORK? B A C K G R O U N D E R
AFATINIB* B A C K G R O U N D E R 1. What is afatinib? 2. How does afatinib work? 3. Data overview: the LUX-Lung clinical trial programme 4. Data overview: the LUX-Head and Neck clinical trial programme
More informationEGFR-M+ NSCLC: Mechanistic and Clinical Considerations for Choosing the Best TKI
EGFR-M+ NSCLC: Mechanistic and Clinical Considerations for Choosing the Best TKI 217 Conversations in Oncology in Shanghai, China Dr. Daniel SW Tan Division of Medical Oncology, National Cancer Centre
More informationOverall survival with afatinib versus chemotherapy in patients with NSCLC harboring common EGFR
Overall survival with afatinib versus chemotherapy in patients with NSCLC harboring common EGFR mutations: subgroup analyses by race/ethnicity in LUX-Lung 3 and LUX-Lung 6 Yi-Long Wu, 1 Lecia V Sequist,
More informationSuccesses and Challenges in Treating Squamous Cell Carcinoma of the Lung
Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung Noemi Reguart,MD, PhD Hospital Clinic de Barcelona Barcelona, Spain SC-CRP-02660 Conversations in Oncology 2018 is a standalone
More informationTargeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont. Masterclass 27 september 2018
Targeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont Masterclass 27 september 2018 Outline Introduction EGFR TKI ALK TKI TKI for uncommon driver mutations Take home messages The promise of
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationOptimum Sequencing of EGFR targeted therapy in NSCLC. Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey
Optimum Sequencing of EGFR targeted therapy in NSCLC Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey Lung cancer NSCLC SCLC adeno squamous EGFR ALK ROS1 BRAF HER2 KRAS EGFR Transl Lung Cancer
More informationJ. C.-H. Yang 1, L.V. Sequist 2, S. L. Geater 3, C.-M. Tsai 4, T. Mok 5, M. H. Schuler 6, N. Yamamoto 7, D. Massey 8, V. Zazulina 8, Yi-Long Wu 9
Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: Findings from three prospective trials of afatinib in EGFR mutation-positive lung cancer J. C.-H. Yang 1, L.V. Sequist
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationPost-marketing observational study of Japanese patients with EGFR mutation-positive (EGFRm+) NSCLC treated with daily afatinib (final report)
Post-marketing observational study of Japanese patients with EGFR mutation-positive (EGFRm+) NSCLC treated with daily afatinib (final report) Nobuyuki Yamamoto, 1 Toshihiro Nukiwa, 2 Yoichi Nakanishi,
More informationLudger Sellmann 1, Klaus Fenchel 2, Wolfram C. M. Dempke 3,4. Editorial
Editorial Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer the Holy Grail in cancer treatment? Ludger Sellmann 1, Klaus Fenchel
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationTarget therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy)
Target therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) cgridelli@libero.it First-Line Treatment of Advanced NSCLC EGFR-mutation analysis
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationSequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the GioTag study
Scan the QR code for an electronic copy of the poster and supplementary material Sequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the
More informationTargeted Therapy for NSCLC: EGFR and ALK Fadlo R. Khuri, MD
EGFR and ALK Fadlo R. Khuri, MD President, American University of Beirut Professor of Medicine July 26, 2018 A great year end! Targeted Therapy for NSCLC: Evolving Landscape of Lung Adenocarcinoma NSCLC
More informationIMPORTANT PATHWAYS TO TARGET IN (ADVANCED) NSCLC:
IMPORTANT PATHWAYS TO TARGET IN (ADVANCED) NSCLC: A focus on EGFR-inhibition and implications for clinical practice Floriana Morgillo, MD PhD and Morena Fasano, MD PhD Faculty of Medicine, Università degli
More informationDo You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
More informationSlide 1. Slide 2. Slide 3. Disclosures. Personalized Medicine for Advanced NSCLC in East Asia. No conflicts related to this presentation
Slide 1 12 th International Lung Cancer Conference Personalized Medicine for Advanced NSCLC in East Asia Masahiro Tsuboi, M.D., Ph.D. Group Chair, Lung Cancer Surgical Study Group in Japan Clinical Oncology
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationConsiderations for Choosing TKIs for Squamous NSCLC in the Era of Immunotherapy: Which Patients Could Benefit?
Considerations for Choosing TKIs for Squamous NSCLC in the Era of Immunotherapy: Which Patients Could Benefit? Barbara Melosky University of British Columbia, British Columbia Cancer Agency Faculty Disclosure
More informationNational Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan;
Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, and 7 James C.-H. Yang, 1 Yi-Long Wu, 2 Vera Hirsh,
More informationAFATINIB FOLLOWED BY OSIMERTINIB IN REAL-WORLD PATIENTS WITH EGFR MUTATION-POSITIVE NSCLC: AN OBSERVATIONAL STUDY
AFATINIB FOLLOWED BY OSIMERTINIB IN REAL-WORLD PATIENTS WITH EGFR MUTATION-POSITIVE NSCLC: AN OBSERVATIONAL STUDY Maximilian J. Hochmair, 1 Alessandro Morabito, 2 Desiree Hao, 3 Cheng-Ta Yang, 4 Ross A.
More informationPersonalized Medicine: Lung Biopsy and Tumor
Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the
More informationThe road less travelled: what options are available for patients with advanced squamous cell carcinoma?
Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Disclosures Honoraria for advisory board/consulting
More informationLung Cancer Update 2016 BAONS Oncology Care Update
Lung Cancer Update 2016 BAONS Oncology Care Update Matthew Gubens, MD, MS Assistant Professor Chair, Thoracic Oncology Site Committee UCSF Helen Diller Family Comprehensive Cancer Center Disclosures Consulting
More informationOsimertinib as first-line treatment of EGFR mutant advanced nonsmall-cell
Editorial Osimertinib as first-line treatment of EGFR mutant advanced nonsmall-cell lung cancer Chong-Kin Liam Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationPage: 1 of 27. Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer
Last Review Status/Date: December 2014 Page: 1 of 27 Non-Small-Cell Lung Cancer Description Over half of patients with non-small-cell lung cancer (NSCLC) present with advanced and therefore incurable disease,
More informationA case of different EGFR mutations in surgically resected synchronous triple lung cancer
Case Report A case of different EGFR mutations in surgically resected synchronous triple lung cancer Naoki Haratake 1, Mitsuhiro Takenoyama 1, Makoto Edagawa 1, Shinichiro Shimamatsu 1, Ryo Toyozawa 1,
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationTargeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care
Targeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland
More informationGIOTRIF (AFATINIB*) For journalists outside the US/UK/Canada only 1. WHAT IS GIOTRIF (AFATINIB*)? 2. HOW DOES GIOTRIF (AFATINIB*) WORK?
For journalists outside the US/UK/Canada only GIOTRIF (AFATINIB*) 1. What is GIOTRIF (afatinib*)? 2. How does GIOTRIF (afatinib*) work? 3. Data overview 4. Clinical potential 5. GIOTRIF (afatinib*) approval
More informationFrequency of Epidermal Growth Factor Mutation Status and Its Effect on Outcome of Patients with Adenocarcinoma of the Lung
Journal of Cancer Therapy, 2014, 5, 1012-1020 Published Online September 2014 in SciRes. http://www.scirp.org/journal/jct http://dx.doi.org/10.4236/jct.2014.511106 Frequency of Epidermal Growth Factor
More informationNCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018
Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as
More informationQuale sequenza terapeutica nella malattia EGFR+
Trattamento della malattia avanzata oncogene-addicted Quale sequenza terapeutica nella malattia EGFR+ Chiara Bennati AUSL della Romagna Ravenna, Italy A matter of fact Outline Can we improve PFS/OS with
More informationMedical Policy. MP Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer
Medical Policy MP 2.04.45 BCBSA Ref. Policy: 2.04.45 Last Review: 10/30/2017 Effective Date: 10/30/2017 Section: Medicine Related Policies 2.04.115 Molecular Panel Testing of Cancers to Identify Targeted
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationEpidermal growth factor receptor (EGFR) mutations are
Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3 Terufumi Kato, 1 Hiroshige Yoshioka,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer Page 1 of 52 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Molecular Analysis for Targeted
More informationRecent Advances in Lung Cancer: Updates from ASCO 2017
Recent Advances in Lung Cancer: Updates from ASCO 2017 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/15/2017
More informationCURRENT STANDARD OF CARE OF LUNG CANCER. Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff
CURRENT STANDARD OF CARE OF LUNG CANCER Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff Biopsy: Establish Diagnosis, Determine Histologic Subtype,
More informationMolecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer
Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer Policy Number: 2.04.45 Last Review: 3/2018 Origination: 3/2013 Next Review: 3/2019 Policy Blue Cross and Blue Shield of Kansas City
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationPersonalized Medicine for Advanced NSCLC in East Asia
Personalized Medicine for Advanced NSCLC in East Asia - Update treatment strategy for NSCLC based on Japanese clinical practice guideline - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine,
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationOriginal Article. Abstract
Japanese Journal of Clinical Oncology, 2015, 45(7) 670 676 doi: 10.1093/jjco/hyv054 Advance Access Publication Date: 15 April 2015 Original Article Original Article Efficacy of chemotherapy after first-line
More informationNon-Small Cell Lung Cancer:
Non-Small Cell Lung Cancer: Where We Are Today Sila Shalhoub, PharmD PGY2 Oncology Pharmacy Resident Shalhoub.Sila@mayo.edu Pharmacy Grand Rounds September 26, 2017 2017 MFMER slide-1 Objectives Identify
More informationNCCN Non Small Cell Lung Cancer V Meeting July 8, 2016
NSCL 3 Submission from Myriad requesting the following statement to be listed as an additional high risk factor in footnote p : For lung ADC, a highrisk 46 gene molecular prognostic score determined by
More informationNew options for old and new targets in NSCLC Rosario García Campelo Medical Oncology Unit University Hospital A Coruña
New options for old and new targets in NSCLC Rosario García Campelo Medical Oncology Unit University Hospital A Coruña Phase II GOAL TRIAL DESIGN Key inclusion criteria Patients with locally advanced or
More informationCompeting CNS or systemic progression analysis for EGFR mutation-positive NSCLC patients on afatinib in LUX-Lung 3, 6, and 7
Competing CNS or systemic progression analysis for EGFR mutation-positive NSCLC patients on afatinib in LUX-Lung 3, 6, and 7 Diego Kaen, 1 James C.-H. Yang, 2 Yi-Long Wu, 3 Vera Hirsh, 4 Kenneth O Byrne,
More informationPresented at the European Society of Medical Oncology (ESMO), Munich, Germany, October 2018
Effectiveness of afatinib in clinical practice first results of the GIDEON trial: a prospective non-interventional study in EGFR-mutated NSCLC in Germany Wolfgang M. Brueckl 1 *, Eckart Laack 2, Martin
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationTargeting Acquired Resistance to EGFR Kinase Inhibitors: Beyond T790M Mutation
Targeting Acquired Resistance to EGFR Kinase Inhibitors: Beyond T790M Mutation James Chih-Hsin Yang, MD, PhD National Taiwan University Hospital National Taiwan University Cancer Center Taipei, Taiwan
More informationINNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
More informationNext Generation EGFR Inhibitors
Next Generation EGFR Inhibitors Tony Mok MD Li Shu Fan Medical Foundation Professor of Clinical Oncology Dept. of Clinical Oncology The Chinese University of Hong Kong EGFR TKIs First Generation -Gefitinib
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationSecond-line afatinib for advanced squamous cell carcinoma of the lung: analysis of afatinib long-term responders in the Phase III LUX-Lung 8 trial
Second-line afatinib for advanced squamous cell carcinoma of the lung: analysis of afatinib long-term responders in the Phase III LUX-Lung 8 trial lenwood oss, Manuel Cobo, Shun Lu, Konstantinos Syrigos,
More informationAURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?
Editorial Page 1 of 5 AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC? Terry L. Ng, D. Ross Camidge Division of Medical Oncology, Department of Medicine, University of Colorado
More informationTargeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
More informationMolecular Analysis for Targeted Therapy for Non- Small-Cell Lung Cancer Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory
2.04.45 Molecular Analysis for Targeted Therapy for Non- Small-Cell Lung Cancer Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory Effective Date November 26, 2014 Original Policy Date November
More informationCarmen Salvador-Coloma 1,2, David Lorente 1,2, Sarai Palanca 3, Javier Simarro 3, Nuria Mancheño 4, Juan Sandoval 5, Agustín Lahoz 5, Óscar Juan 2,5
Original Article Early radiological response as predictor of overall survival in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor mutations Carmen Salvador-Coloma 1,2,
More informationAgenda. 6:30pm 7:00pm. Dinner. 7:00pm 7:15pm. NSCLC Treatment in 2014: Focus on Use of 2nd Generation TKIs in Clinical Practice.
Agenda 6:30pm 7:00pm Dinner 7:00pm 7:15pm Welcome and Introductions Natasha Leighl, MD 7:15pm 7:50pm 7:50pm 8:00pm NSCLC Treatment in 2014: Focus on Use of 2nd Generation TKIs in Clinical Practice Questions
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationSummary of the risk management plan (RMP) for Tagrisso (osimertinib)
EMA/2497/2016 Summary of the risk management plan (RMP) for Tagrisso (osimertinib) This is a summary of the risk management plan (RMP) for Tagrisso, which details the measures to be taken in order to ensure
More informationPROGRESSION AFTER THIRD GENERATION TKI
PROGRESSION AFTER THIRD GENERATION TKI What next? National Cancer Center Hospital Yuichiro Ohe, MD Name of lead presenter Yuichiro Ohe employee of company and/or profit-making organization adviser of company
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationTreatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line
Treatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line Martin Reck David F. Heigener Department of Thoracic Oncology Hospital Grosshansdorf Germany Identification of driver mutation in tumor specimens
More informationPersonalized Treatment Approaches for Lung Cancer
Personalized Treatment Approaches for Lung Cancer California Thoracic Society 2018 Annual Carmel Conference January 27, 2018 Matthew Gubens, MD, MS Associate Professor of Medicine Chair, Thoracic Oncology
More informationOTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento
OTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento Dolores Isla Servicio de Oncología Médica HCU Lozano Besa de Zaragoza 2008 Selection Factors in Advanced NSCLC ( 8y ago)
More informationIn the last decade, the emergence of targeted therapies has changed the treatment paradigm for non-small cell lung cancer (NSCLC).
Immunotherapy and Targeted Therapies in the Treatment of Non-small Cell Lung Cancer Tu Nguyen-Ngoc, 1 Martin Reck, 2 Daniel SW Tan 3 and Solange Peters 1 1. Department of Medical Oncology, Centre Hospitalier
More informationThe oncologist s point of view: the promise and challenges of increasing options for targeted therapies in NSCLC
The oncologist s point of view: the promise and challenges of increasing options for targeted therapies in NSCLC Egbert F. Smit Department of Thoracic Oncology, Netherlands Cancer Institute, and Department
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More information1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science
More information